Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12718709 | 0.89 | PDE4A (0.33) | ALOX5APFEN1PDE4APDE4BPDE4C | |
| SCHEMBL12823748 | 0.86 | GRIN2B (0.33) | GRIN2BCYP17A1 | |
| SCHEMBL12823044 | 0.85 | PDE4A (0.30) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12823491 | 0.85 | PDE4A (0.30) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12823180 | 0.85 | ESR1 (0.33) | GRIN2BGRIN1PDE4APDE4BPDE4C | |
| SCHEMBL12823649 | 0.84 | SERPINE1 (0.34) | GRIN2BGRIN1ALOX5APFEN1PDE4A | |
| SCHEMBL12719334 | 0.84 | GABRA1 (0.33) | ALOX5APFEN1PDE4APDE4BPDE4C | |
| SCHEMBL12719343 | 0.84 | GABRA1 (0.33) | ALOX5APFEN1PDE4APDE4BPDE4C | |
| SCHEMBL12823012 | 0.83 | DRD4 (0.32) | ALOX5APFEN1 | |
| SCHEMBL10303332 | 0.82 | SIGMAR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | GRIN2B 1871/4885GRIN1 1597/4885ALOX5AP 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.